IsoRay

IsoRay is a United States medical-isotope company associated with the development, manufacture, and sale of brachytherapy products. Its principal business is based on radioactive sources used in localized radiation treatment, a method in which sealed radioactive material is placed inside or near a tumor to deliver therapeutic radiation directly to the treatment site. The company is described as the sole producer of cesium brachytherapy sources and markets its brachytherapy isotopes under the Blu brand. The company’s role sits at the intersection of isotope production, medical-device manufacturing, and oncology treatment. Rather than operating as a hospital system or a broad pharmaceutical company, IsoRay is primarily a specialist supplier of products used by medical professionals in radiation oncology. Its products are intended to support treatments for cancers that may be difficult to manage with external-beam radiation or other conventional approaches, although the specific clinical indications and commercial scope depend on the applicable device clearances and treatment protocols. IsoRay is identified as a registered manufacturer with the United States Food and Drug Administration and has held multiple 510(k) clearances for brachytherapy devices. These clearances are relevant to the company’s ability to market particular medical devices in the United States, but they do not by themselves establish that every product is cleared for every cancer type or clinical use. The supplied reference material does not provide a complete catalogue of the company’s devices, the dates of individual clearances, clinical outcomes, manufacturing capacity, or current commercial reach. IsoRay went public in 2005. No ticker symbol, exchange, current ownership structure, or subsequent corporate status is established by the available material. Its corporate headquarters is reported at 350 Hills Street, Suite 106, in Richland, Washington. The available reference information is concentrated on the company’s corporate identity, regulatory position, and cesium-brachytherapy business, so details about management, financial performance, international operations, partnerships, marketing campaigns, and later strategic developments remain undocumented here.

IsoRay is described as a national isotope-based medical company headquartered in Richland, Washington. Its business is centered on brachytherapy, a form of radiation treatment that uses sealed radioactive sources positioned within or close to a tumor. The company’s principal distinction in the supplied reference material is its production of cesium brachytherapy sources, which are intended to expand the use of brachytherapy in the treatment of cancers that can be challenging to treat. The company’s products are sold under the Blu brand. This brand encompasses the company’s brachytherapy isotope offering, while the broader IsoRay identity represents the corporate and manufacturing organization behind the products. The available material does not specify the original incorporation date, founders, early financing, research institutions, or the development history of the cesium platform. IsoRay became a public company in 2005. The supplied sources do not identify the exchange, ticker, offering structure, valuation, or subsequent trading history. They also do not provide enough information to establish whether the company remains publicly listed or whether its corporate structure has changed since the reported public offering. From a regulatory perspective, IsoRay is identified as a registered manufacturer with the United States Food and Drug Administration. It has held multiple 510(k) clearances for brachytherapy devices. These clearances indicate that specific devices were reviewed under the FDA’s 510(k) pathway, but the available reference does not list the individual device names, clearance dates, predicates, or approved indications. Accordingly, IsoRay’s regulatory history can be characterized only at a high level. The company’s reported headquarters is at 350 Hills Street, Suite 106, Richland, Washington 99354. No reliable information in the supplied material establishes its present operating markets, current management, parent company, owner, financial results, partnerships, acquisitions, litigation, recalls, or promotional campaigns. The available record therefore supports a focused account of IsoRay as a specialist cesium-brachytherapy and medical-device company, but not a complete chronology of its later corporate development.

• 2005

  IsoRay went public

  [1]IsoRayen.wikipedia.org

  IsoRay is reported to have become a public company in 2005. The supplied source does not identify the exchange, ticker, offering details, or subsequent listing status.

A specialist medical-isotope and radiation-oncology supplier centered on cesium brachytherapy sources and related cleared devices.

• Brachytherapy isotope

  Blu cesium brachytherapy sources

  Blu is the brand under which IsoRay’s brachytherapy isotopes are marketed. The company is described as the sole producer of cesium brachytherapy sources. These sealed radioactive sources are used in localized radiation treatment, where the source is placed in or near a tumor to deliver radiation to the target area. The supplied material does not specify individual product configurations, indications, or current availability.

• Radiation-therapy medical device

  Brachytherapy devices

  IsoRay has held multiple FDA 510(k) clearances for brachytherapy devices. These devices support the clinical use or delivery of radioactive sources in localized cancer treatment. The available reference does not identify each cleared device or describe its technical design, clinical indication, or commercial lifecycle, so this entry represents the product category rather than a complete device catalogue.

1. 1IsoRayen.wikipedia.org